Sridhar Bolla, MD
Hematology & Oncology · Avon, INNPI 1316994148
Payments from drug & device makers
Across 1,222 payments — averaging $175.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$61K
- Incyte Corporation$59K
- Radius Health, Inc.$27K
- EMD Serono, Inc.$26K
- Astrazeneca UK Limited$16K
- Novartis$4K
- plus $21K from 54 others
What the payments were for
- Speaking & faculty fees$3,20011%
- Travel & lodging$3961%
- Food & beverage$21,78276%
- Education$6942%
- Other$2,4669%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$213,961 in reported general payments places this provider in the 80th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 30 | $787,131 |
| VerzenioAbemaciclib | 45 | $714,941 |
| Lenalidomide | 38 | $491,723 |
| IdhifaEnasidenib Mesylate | 12 | $473,334 |
| ImbruvicaIbrutinib | 26 | $424,485 |
| JakafiRuxolitinib Phosphate | 20 | $336,093 |
| CalquenceAcalabrutinib Maleate | 23 | $319,887 |
| XtandiEnzalutamide | 26 | $296,484 |
| EliquisApixaban | 276 | $253,949 |
| KisqaliRibociclib Succinate | 13 | $213,649 |
| XareltoRivaroxaban | 208 | $187,366 |
| BrukinsaZanubrutinib | 11 | $160,869 |
| ReblozylLuspatercept-Aamt | 11 | $131,949 |
| BosulifBosutinib | 12 | $122,811 |
| OrgovyxRelugolix | 11 | $30,688 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $695 | $787,13130 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $468 | $715,60384 claims |
| Bristol Myers SquibbIdhifa | $651 | $473,33412 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $236 | $424,48526 claims |
| PfizerEliquis, Bosulif | $946 | $376,759288 claims |
| Incyte CorporationJakafi | $58,943 | $336,09320 claims |
| AstraZenecaCalquence | $1,231 | $319,88723 claims |
| Astellas Pharma US IncXtandi | $250 | $296,48426 claims |
| NovartisKisqali | $4,371 | $213,64913 claims |
| Johnson & JohnsonXarelto | $1,063 | $187,366208 claims |
| Beigene USA, Inc.Brukinsa | $118 | $160,86911 claims |
| E.r. Squibb & Sons, L.L.C.Reblozyl | $60,615 | $131,94911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Avon
- Seyed Hamid SayarAvon$422K
- Gregory DurmIndianapolis$22.7M
- Nabil AdraIndianapolis$13.2M
- Attaya SuvannasankhaIndianapolis$8.2M
- Zhentao ZhangFort Wayne$6.4M
- Shadia JalalIndianapolis$4.6M
- Ahad SadiqFort Wayne$4M
- Ruemu BirhirayIndianapolis$4M
- Richard GaynorIndianapolis$3.7M
- Ebenezer KioGoshen$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.